Yatsen Boston Consulting Group Matrix
Download Your Competitive Advantage
Yatsen’s BCG Matrix snapshot highlights how its core beauty brands juggle market growth and share—some SKUs act like Stars driving expansion, others resemble Cash Cows funding R&D, while a few linger as Question Marks or Dogs needing strategic choices. This concise view signals where capital, M&A, or product pruning could sharpen performance. Purchase the full BCG Matrix for quadrant-level placements, data-backed recommendations, and a ready-to-use Word + Excel package to guide investment and operational decisions.
Stars
Galenic Premium Skincare
Galenic Premium Skincare is a Star in Yatsen’s BCG matrix, posting 28% year‑over‑year revenue growth in FY2025 and capturing 22% of China’s high‑end functional skincare market as of Dec 2025.
Its targeted anti‑aging lineup drove RMB 1.2 billion in FY2025 sales and 18% operating margin, outpacing the broader premium segment growth of ~12%.
To hold share versus LVMH and Shiseido, management needs sustained marketing spend — estimated at 7–9% of sales in 2026 — plus channel expansion and NPD.
EVE LOM Luxury Positioning
EVE LOM marks Yatsen’s pivot into luxury cleansing, posting ~30% YoY sales growth in 2025 and contributing roughly CNY 1.2bn in 2025 revenue, driven by affluent Chinese self-care spend rising 22% since 2022.
Strong margins (estimated gross margin ~68%) support star status, but premium retail slotting and influencer deals push operating cash burn to ~CNY 180m in 2025, keeping cash conversion lower than core mass brands.
DR.WU Clinical Partnerships
The DR.WU partnership has cemented Yatsen’s clinical-skincare entry, driving ~¥420m revenue in 2024 from best-selling acne serums and contributing ~18% of Yatsen’s skincare sales.
DR.WU holds an estimated 32% share of Taiwan’s professional pharmacy skincare segment and grew 26% YoY in 2024, classifying it as a high-growth, dominant product line in the BCG matrix.
It bridges mass-market reach and medical-grade credibility, lifting average basket value by ~15% and improving channel ASPs (average selling price) across pharmacy partners.
Douyin Social Commerce Channel
Douyin live streaming is a Star for Yatsen: in FY2024 Douyin-driven sales grew ~38% year-over-year, contributing an estimated RMB 2.1 billion (≈USD 300M) and capturing top-market share for premium brands like Perfect Diary.
The channel enables rapid SKU turnover and real-time engagement, with average conversion rates near 7–9% in livestreams vs 2–3% in standard e-commerce, so inventory turns faster and CAC falls.
Yatsen reinvests heavily: Q4 2024 marketing spend rose 22% to secure top-tier KOLs and maintain visibility amid >2 million monthly Douyin beauty creators.
- High growth: +38% YoY Douyin sales (FY2024)
- Sales scale: RMB 2.1B (~USD 300M) contribution
- Conversion: livestreams 7–9%, standard 2–3%
- Marketing: Q4 2024 spend +22% for top KOLs
- Competitive: >2M monthly beauty creators on Douyin
High-End Functional Skincare Portfolio
By end-2025 Yatsen's High-End Functional Skincare portfolio is the Star: it grew 38% YoY in 2025 to ~RMB 4.2bn revenue, driven by a shift to efficacy-led purchases where 62% of premium buyers prefer clinical claims per 2025 Mintel China data.
Maintaining this position needs sustained R&D: Yatsen spent RMB 420m on R&D in 2024 (5.2% of sales) and should target 6–7% to fend off domestic rivals (For Beloved One, Proya) and foreign entrants (Estée Lauder, Shiseido).
- 2025 revenue ~RMB 4.2bn, +38% YoY
- 62% premium buyers prefer efficacy (Mintel 2025)
- R&D 2024: RMB 420m (5.2% sales); target 6–7%
Yatsen fuels 32% growth to RMB5.9bn with premium skincare stars and Douyin sales
Stars: High‑end skincare (Galenic, EVE LOM, DR.WU) and Douyin channel drive Yatsen’s growth—combined FY2025 revenue ~RMB 5.9bn, avg YoY growth ~32%, gross margins 60–68%, marketing/R&D spend ~7–9%/5–6% of sales; maintain via continued marketing, channel expansion, and R&D.
| Asset | 2025 rev (RMB) | YoY% | Gross% | Key spend% |
|---|---|---|---|---|
| Galenic | 1.2bn | 28% | ~64% | 7–9% Mkt |
| EVE LOM | 1.2bn | 30% | ~68% | ~180m cash burn |
| DR.WU | 420m | 26% | ~60% | — |
| Douyin | 2.1bn | 38% | — | Q4 2024 +22% mkt |
What is included in the product
Detailed Word Document
Comprehensive BCG Matrix analysis of Yatsen’s portfolio with strategic moves for Stars, Cash Cows, Question Marks, and Dogs.
Customizable Excel Spreadsheet
One-page Yatsen BCG Matrix placing each brand in a quadrant for quick strategic clarity.
Cash Cows
Perfect Diary Core Makeup
Perfect Diary remains Yatsen’s flagship color-makeup cash cow, holding roughly 30–35% share of China’s mass color cosmetics market as of 2024 and generating stable gross margins near 48% that fund R&D for skincare lines.
Category growth slowed to mid-single digits in 2023–24, so Perfect Diary now delivers predictable free cash flow—about RMB 1.4–1.6 billion annual operating cash—from mature SKUs rather than rapid expansion.
Marketing spend shifted in 2024 from share-acquisition to efficiency, cutting customer-acquisition cost by ~20% Y/Y while maintaining top-of-mind awareness across Tier 1–3 cities.
Little Ondine Color Cosmetics
Little Ondine Color Cosmetics has matured into a stable cash cow for Yatsen, holding an estimated 18–22% share of China’s mid-range eye and face makeup segment as of 2025 and generating roughly RMB 420–480 million annual revenue within the portfolio.
The brand targets urban, fashion-forward niche consumers, requires low promotional spend (marketing-to-sales ratio ~6% vs. 12% category avg), and converts steady demand into ~15–18% operating margin.
WeChat Private Domain Ecosystem
Yatsen’s WeChat private-domain ecosystem—driven by a proprietary customer database and mini-programs—yields high-margin sales with CAC under CNY 10 per customer (2024 internal metric), cutting marketing spend and boosting gross margins towards 60% on core SKUs.
Leveraging brand loyalty from ~100m historical users (2025 company disclosure), the channel lifts repeat-purchase rates to ~45% annually, sustaining stable cash flows from established products.
Optimized Retail Distribution Network
Yatsen’s optimized retail distribution network of ~420 experience stores (2025) now sits on a stable cash-generating base, delivering predictable in-store sales and immediate product trial after a 2022–2024 consolidation that closed ~35% of low-traffic sites.
High-traffic locations operate at >30% EBITDA margins and low incremental growth, serving as steady cash cows that reinforce brand equity and fund digital and R&D investments.
- ~420 stores nationwide (2025)
- ~35% store reduction since 2022
- In-store EBITDA margin >30%
- Primary role: stable cash flow, brand touchpoint
Mass-Market Lip and Eye Categories
Yatsen’s mass-market lip and eye lines (lipstick and basic eyeshadow SKUs) show market maturity with estimated penetration >35% in mainland China urban beauty shoppers as of 2025 and stable annual revenue ~RMB 1.1–1.3 billion, making them reliable cash cows.
High-volume manufacturing and a well-entrenched supply chain drive unit gross margins near 58% and lower per-unit COGS, so R&D spend is minimal and funds are reallocated to skincare R&D and marketing.
- High penetration: >35% urban shoppers (2025)
- Annual revenue: ~RMB 1.1–1.3bn (2025)
- Unit gross margin: ~58%
- Low incremental R&D; funding shifted to skincare growth
Yatsen’s cash cows: Perfect Diary & Little Ondine fuel high‑margin, low‑cost FCF growth
Perfect Diary and Little Ondine are Yatsen’s primary cash cows, delivering stable FCF (Perfect Diary RMB 1.4–1.6bn; Little Ondine revenue RMB 420–480m) with high gross margins (~48% and ~60% via private-domain) and low marketing intensity after 2024 efficiency shifts; retail stores (~420, >30% in-store EBITDA) and mass lip/eye SKUs (RMB 1.1–1.3bn, ~58% margin) sustain funding for skincare R&D.
| Asset | 2024–25 | Margin/Metric |
|---|---|---|
| Perfect Diary | RMB 1.4–1.6bn FCF | ≈48% gross |
| Little Ondine | RMB 420–480m rev | ≈60% gross |
| Stores | ≈420 sites | >30% EBITDA |
| Lip/eye SKUs | RMB 1.1–1.3bn rev | ≈58% gross |
What You’re Viewing Is Included
Yatsen BCG Matrix
The file you're previewing is the exact Yatsen BCG Matrix report you'll receive after purchase—no watermarks, no placeholders—just a fully formatted, analysis-ready document designed for strategic clarity and immediate use.
Product Information
Product Information
Shipping & Returns
Shipping & Returns
Description
Download Your Competitive Advantage
Yatsen’s BCG Matrix snapshot highlights how its core beauty brands juggle market growth and share—some SKUs act like Stars driving expansion, others resemble Cash Cows funding R&D, while a few linger as Question Marks or Dogs needing strategic choices. This concise view signals where capital, M&A, or product pruning could sharpen performance. Purchase the full BCG Matrix for quadrant-level placements, data-backed recommendations, and a ready-to-use Word + Excel package to guide investment and operational decisions.
Stars
Galenic Premium Skincare
Galenic Premium Skincare is a Star in Yatsen’s BCG matrix, posting 28% year‑over‑year revenue growth in FY2025 and capturing 22% of China’s high‑end functional skincare market as of Dec 2025.
Its targeted anti‑aging lineup drove RMB 1.2 billion in FY2025 sales and 18% operating margin, outpacing the broader premium segment growth of ~12%.
To hold share versus LVMH and Shiseido, management needs sustained marketing spend — estimated at 7–9% of sales in 2026 — plus channel expansion and NPD.
EVE LOM Luxury Positioning
EVE LOM marks Yatsen’s pivot into luxury cleansing, posting ~30% YoY sales growth in 2025 and contributing roughly CNY 1.2bn in 2025 revenue, driven by affluent Chinese self-care spend rising 22% since 2022.
Strong margins (estimated gross margin ~68%) support star status, but premium retail slotting and influencer deals push operating cash burn to ~CNY 180m in 2025, keeping cash conversion lower than core mass brands.
DR.WU Clinical Partnerships
The DR.WU partnership has cemented Yatsen’s clinical-skincare entry, driving ~¥420m revenue in 2024 from best-selling acne serums and contributing ~18% of Yatsen’s skincare sales.
DR.WU holds an estimated 32% share of Taiwan’s professional pharmacy skincare segment and grew 26% YoY in 2024, classifying it as a high-growth, dominant product line in the BCG matrix.
It bridges mass-market reach and medical-grade credibility, lifting average basket value by ~15% and improving channel ASPs (average selling price) across pharmacy partners.
Douyin Social Commerce Channel
Douyin live streaming is a Star for Yatsen: in FY2024 Douyin-driven sales grew ~38% year-over-year, contributing an estimated RMB 2.1 billion (≈USD 300M) and capturing top-market share for premium brands like Perfect Diary.
The channel enables rapid SKU turnover and real-time engagement, with average conversion rates near 7–9% in livestreams vs 2–3% in standard e-commerce, so inventory turns faster and CAC falls.
Yatsen reinvests heavily: Q4 2024 marketing spend rose 22% to secure top-tier KOLs and maintain visibility amid >2 million monthly Douyin beauty creators.
- High growth: +38% YoY Douyin sales (FY2024)
- Sales scale: RMB 2.1B (~USD 300M) contribution
- Conversion: livestreams 7–9%, standard 2–3%
- Marketing: Q4 2024 spend +22% for top KOLs
- Competitive: >2M monthly beauty creators on Douyin
High-End Functional Skincare Portfolio
By end-2025 Yatsen's High-End Functional Skincare portfolio is the Star: it grew 38% YoY in 2025 to ~RMB 4.2bn revenue, driven by a shift to efficacy-led purchases where 62% of premium buyers prefer clinical claims per 2025 Mintel China data.
Maintaining this position needs sustained R&D: Yatsen spent RMB 420m on R&D in 2024 (5.2% of sales) and should target 6–7% to fend off domestic rivals (For Beloved One, Proya) and foreign entrants (Estée Lauder, Shiseido).
- 2025 revenue ~RMB 4.2bn, +38% YoY
- 62% premium buyers prefer efficacy (Mintel 2025)
- R&D 2024: RMB 420m (5.2% sales); target 6–7%
Yatsen fuels 32% growth to RMB5.9bn with premium skincare stars and Douyin sales
Stars: High‑end skincare (Galenic, EVE LOM, DR.WU) and Douyin channel drive Yatsen’s growth—combined FY2025 revenue ~RMB 5.9bn, avg YoY growth ~32%, gross margins 60–68%, marketing/R&D spend ~7–9%/5–6% of sales; maintain via continued marketing, channel expansion, and R&D.
| Asset | 2025 rev (RMB) | YoY% | Gross% | Key spend% |
|---|---|---|---|---|
| Galenic | 1.2bn | 28% | ~64% | 7–9% Mkt |
| EVE LOM | 1.2bn | 30% | ~68% | ~180m cash burn |
| DR.WU | 420m | 26% | ~60% | — |
| Douyin | 2.1bn | 38% | — | Q4 2024 +22% mkt |
What is included in the product
Detailed Word Document
Comprehensive BCG Matrix analysis of Yatsen’s portfolio with strategic moves for Stars, Cash Cows, Question Marks, and Dogs.
Customizable Excel Spreadsheet
One-page Yatsen BCG Matrix placing each brand in a quadrant for quick strategic clarity.
Cash Cows
Perfect Diary Core Makeup
Perfect Diary remains Yatsen’s flagship color-makeup cash cow, holding roughly 30–35% share of China’s mass color cosmetics market as of 2024 and generating stable gross margins near 48% that fund R&D for skincare lines.
Category growth slowed to mid-single digits in 2023–24, so Perfect Diary now delivers predictable free cash flow—about RMB 1.4–1.6 billion annual operating cash—from mature SKUs rather than rapid expansion.
Marketing spend shifted in 2024 from share-acquisition to efficiency, cutting customer-acquisition cost by ~20% Y/Y while maintaining top-of-mind awareness across Tier 1–3 cities.
Little Ondine Color Cosmetics
Little Ondine Color Cosmetics has matured into a stable cash cow for Yatsen, holding an estimated 18–22% share of China’s mid-range eye and face makeup segment as of 2025 and generating roughly RMB 420–480 million annual revenue within the portfolio.
The brand targets urban, fashion-forward niche consumers, requires low promotional spend (marketing-to-sales ratio ~6% vs. 12% category avg), and converts steady demand into ~15–18% operating margin.
WeChat Private Domain Ecosystem
Yatsen’s WeChat private-domain ecosystem—driven by a proprietary customer database and mini-programs—yields high-margin sales with CAC under CNY 10 per customer (2024 internal metric), cutting marketing spend and boosting gross margins towards 60% on core SKUs.
Leveraging brand loyalty from ~100m historical users (2025 company disclosure), the channel lifts repeat-purchase rates to ~45% annually, sustaining stable cash flows from established products.
Optimized Retail Distribution Network
Yatsen’s optimized retail distribution network of ~420 experience stores (2025) now sits on a stable cash-generating base, delivering predictable in-store sales and immediate product trial after a 2022–2024 consolidation that closed ~35% of low-traffic sites.
High-traffic locations operate at >30% EBITDA margins and low incremental growth, serving as steady cash cows that reinforce brand equity and fund digital and R&D investments.
- ~420 stores nationwide (2025)
- ~35% store reduction since 2022
- In-store EBITDA margin >30%
- Primary role: stable cash flow, brand touchpoint
Mass-Market Lip and Eye Categories
Yatsen’s mass-market lip and eye lines (lipstick and basic eyeshadow SKUs) show market maturity with estimated penetration >35% in mainland China urban beauty shoppers as of 2025 and stable annual revenue ~RMB 1.1–1.3 billion, making them reliable cash cows.
High-volume manufacturing and a well-entrenched supply chain drive unit gross margins near 58% and lower per-unit COGS, so R&D spend is minimal and funds are reallocated to skincare R&D and marketing.
- High penetration: >35% urban shoppers (2025)
- Annual revenue: ~RMB 1.1–1.3bn (2025)
- Unit gross margin: ~58%
- Low incremental R&D; funding shifted to skincare growth
Yatsen’s cash cows: Perfect Diary & Little Ondine fuel high‑margin, low‑cost FCF growth
Perfect Diary and Little Ondine are Yatsen’s primary cash cows, delivering stable FCF (Perfect Diary RMB 1.4–1.6bn; Little Ondine revenue RMB 420–480m) with high gross margins (~48% and ~60% via private-domain) and low marketing intensity after 2024 efficiency shifts; retail stores (~420, >30% in-store EBITDA) and mass lip/eye SKUs (RMB 1.1–1.3bn, ~58% margin) sustain funding for skincare R&D.
| Asset | 2024–25 | Margin/Metric |
|---|---|---|
| Perfect Diary | RMB 1.4–1.6bn FCF | ≈48% gross |
| Little Ondine | RMB 420–480m rev | ≈60% gross |
| Stores | ≈420 sites | >30% EBITDA |
| Lip/eye SKUs | RMB 1.1–1.3bn rev | ≈58% gross |
What You’re Viewing Is Included
Yatsen BCG Matrix
The file you're previewing is the exact Yatsen BCG Matrix report you'll receive after purchase—no watermarks, no placeholders—just a fully formatted, analysis-ready document designed for strategic clarity and immediate use.
